NDA 021462 · Lilly
Alimta
Pemetrexed Disodium · Intravenous
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Feb 4, 2004
Approved uses
9
Original approval plus efficacy supplements
Registered trials
1,474
328 Phase 3, 251 recruiting
FAERS reports
16,927
15,517 serious, 3,495 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 19, 2023.
ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) ALIMTA ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC...
Mechanism: ALIMTA is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 31, 2022 Supplement 55 · Efficacy LetterLabel
- Jan 30, 2019 Supplement 53 · Efficacy LabelLetter
- Jun 4, 2018 Supplement 51 · Efficacy LabelLetter
- Oct 17, 2012 Supplement 39 · Efficacy LetterLabel
- Nov 18, 2011 Supplement 29 · Efficacy LabelLetter
- Mar 17, 2011 Supplement 33 · Efficacy · priority review LetterLabel
- Jul 2, 2009 Supplement 21 · Efficacy LabelLetter
- Sep 26, 2008 Supplement 15 · Efficacy ReviewLetterLabel
- Feb 4, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewOtherPediatric Medical Review
2 products under this application
- ALIMTA · PEMETREXED DISODIUM EQ 500MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
- ALIMTA · PEMETREXED DISODIUM EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruiting
NING LIAcademic, hospital or other
NCT06824792 · 3,000 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 29, 2028
Drug: Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE. · For: Advanced Solid Tumors
Sites: Langfang, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712316 · 1,580 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 2029
Drug: Pumitamig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Concord, California · 366 sites in all
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingCompleted
ECOG-ACRIN Cancer Research GroupResearch network
NCT01107626 · 1,516 participants · Start Oct 25, 2010 · Primary completion Jan 31, 2019
Drug: Paclitaxel; Carboplatin and 2 more · For: Lung Cancer
Sites: Anniston, Alabama; Fairbanks, Alaska; Fairfield, California · 434 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression1,432
- off label use1,238
- death939
- nausea915
- anaemia873
- diarrhoea851
- pancytopenia821
- neutropenia729
- fatigue727
- thrombocytopenia685
- rash681
- dyspnoea670
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 406 |
| 2006 | 368 |
| 2007 | 296 |
| 2008 | 279 |
| 2009 | 469 |
| 2010 | 624 |
| 2011 | 658 |
| 2012 | 952 |
| 2013 | 541 |
| 2014 | 585 |
| 2015 | 1,671 |
| 2016 | 556 |
| 2017 | 736 |
| 2018 | 958 |
| 2019 | 1,371 |
| 2020 | 1,268 |
| 2021 | 1,128 |
| 2022 | 873 |
| 2023 | 691 |
| 2024 | 840 |
| 2025 | 866 |
| 2026 | 660 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Alimta (Pemetrexed Disodium)
2024 spending
$728K
Beneficiaries
27
110 claims
Per beneficiary
$26,956
$1,382.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,697,563 |
| 2021 | $9,849,598 |
| 2022 | $7,434,149 |
| 2023 | $2,107,224 |
| 2024 | $727,804 |
Part B: Alimta* (Pemetrexed Disodium*) · HCPCS J9305
2024 spending
$23.0M
Beneficiaries
13,143
57,657 claims
Per beneficiary
$1,753
2024 ASP limit $4.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $498,510,123 |
| 2021 | $477,381,476 |
| 2022 | $446,004,779 |
| 2023 | $80,574,519 |
| 2024 | $23,045,559 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer.
Zhang YQ, Wu YL, Feng Y, et al. · Cancer Biother Radiopharm 2022 · Randomized Controlled Trial
- Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.
Goedhals L, van Wiyk AL, Smith BL, et al. · Int J Gynecol Cancer 2006 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Activity of pemetrexed (alimta), a new antifolate, against non-small cell lung cancer.
Postmus PE · Lung Cancer 2002 · Clinical Trial, Clinical Trial, Phase II
- Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.
Bajetta E, Celio L, Buzzoni R, et al. · Ann Oncol 2003 · Clinical Trial, Clinical Trial, Phase II
- Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y, Bagust A, Dickson R, et al. · Health Technol Assess 2007 · Systematic Review
- Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer.
Ettinger DS · Oncology (Williston Park) 2000 · Clinical Trial, Clinical Trial, Phase II
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.